The transferrin receptor and the targeted delivery of therapeutic agents against cancer

Autores
Daniels, Tracy R.; Bernabeu, Ezequiel Adrian; Rodríguez, José A.; Patel, Shabnum; Kozman, Maggie; Chiappetta, Diego Andrés; Holler, Eggehard; Ljubimova, Julia Y.; Helguera, Gustavo Fernando; Penichet, Manuel L.
Año de publicación
2012
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: Traditional cancer therapy can be successful in destroying tumors, but can also cause dangerous side effects. Therefore, many targeted therapies are in development. The transferrin receptor (TfR) functions in cellular iron uptake through its interaction with transferrin. This receptor is an attractive molecule for the targeted therapy of cancer since it is upregulated on the surface of many cancer types and is efficiently internalized. This receptor can be targeted in two ways: 1) for the delivery of therapeutic molecules into malignant cells or 2) to block the natural function of the receptor leading directly to cancer cell death. Scope of revie: In the present article we discuss the strategies used to target the TfR for the delivery of therapeutic agents into cancer cells. We provide a summary of the vast types of anti-cancer drugs that have been delivered into cancer cells employing a variety of receptor binding molecules including Tf, anti-TfR antibodies, or TfR-binding peptides alone or in combination with carrier molecules including nanoparticles and viruses. Major conclusions: Targeting the TfR has been shown to be effective in delivering many different therapeutic agents and causing cytotoxic effects in cancer cells in vitro and in vivo. General significance: The extensive use of TfR for targeted therapy attests to the versatility of targeting this receptor for therapeutic purposes against malignant cells. More advances in this area are expected to further improve the therapeutic potential of targeting the TfR for cancer therapy leading to an increase in the number of clinical trials of molecules targeting this receptor. This article is part of a Special Issue entitled Transferrins: molecular mechanisms of iron transport and disorders.
Fil: Daniels, Tracy R.. University of California at Los Angeles; Estados Unidos
Fil: Bernabeu, Ezequiel Adrian. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina
Fil: Rodríguez, José A.. University of California at Los Angeles; Estados Unidos
Fil: Patel, Shabnum. University of California at Los Angeles; Estados Unidos
Fil: Kozman, Maggie. University of California at Los Angeles; Estados Unidos
Fil: Chiappetta, Diego Andrés. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina
Fil: Holler, Eggehard. Cedars Sinai Medical Center; Estados Unidos
Fil: Ljubimova, Julia Y.. Cedars Sinai Medical Center; Estados Unidos
Fil: Helguera, Gustavo Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina
Fil: Penichet, Manuel L.. University of California at Los Angeles; Estados Unidos
Materia
Transferrin Receptor
Cancer
Nanoparticle
Immnunotoxin
Delivery
Conjugate
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/14137
Acceder
id CONICETDig_5ed5d1bc5ff227f0fe0ca72afca156a7
oai_identifier_str oai:ri.conicet.gov.ar:11336/14137
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling The transferrin receptor and the targeted delivery of therapeutic agents against cancerDaniels, Tracy R.Bernabeu, Ezequiel AdrianRodríguez, José A.Patel, ShabnumKozman, MaggieChiappetta, Diego AndrésHoller, EggehardLjubimova, Julia Y.Helguera, Gustavo FernandoPenichet, Manuel L.Transferrin ReceptorCancerNanoparticleImmnunotoxinDeliveryConjugatehttps://purl.org/becyt/ford/2.10https://purl.org/becyt/ford/2Background: Traditional cancer therapy can be successful in destroying tumors, but can also cause dangerous side effects. Therefore, many targeted therapies are in development. The transferrin receptor (TfR) functions in cellular iron uptake through its interaction with transferrin. This receptor is an attractive molecule for the targeted therapy of cancer since it is upregulated on the surface of many cancer types and is efficiently internalized. This receptor can be targeted in two ways: 1) for the delivery of therapeutic molecules into malignant cells or 2) to block the natural function of the receptor leading directly to cancer cell death. Scope of revie: In the present article we discuss the strategies used to target the TfR for the delivery of therapeutic agents into cancer cells. We provide a summary of the vast types of anti-cancer drugs that have been delivered into cancer cells employing a variety of receptor binding molecules including Tf, anti-TfR antibodies, or TfR-binding peptides alone or in combination with carrier molecules including nanoparticles and viruses. Major conclusions: Targeting the TfR has been shown to be effective in delivering many different therapeutic agents and causing cytotoxic effects in cancer cells in vitro and in vivo. General significance: The extensive use of TfR for targeted therapy attests to the versatility of targeting this receptor for therapeutic purposes against malignant cells. More advances in this area are expected to further improve the therapeutic potential of targeting the TfR for cancer therapy leading to an increase in the number of clinical trials of molecules targeting this receptor. This article is part of a Special Issue entitled Transferrins: molecular mechanisms of iron transport and disorders.Fil: Daniels, Tracy R.. University of California at Los Angeles; Estados UnidosFil: Bernabeu, Ezequiel Adrian. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; ArgentinaFil: Rodríguez, José A.. University of California at Los Angeles; Estados UnidosFil: Patel, Shabnum. University of California at Los Angeles; Estados UnidosFil: Kozman, Maggie. University of California at Los Angeles; Estados UnidosFil: Chiappetta, Diego Andrés. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; ArgentinaFil: Holler, Eggehard. Cedars Sinai Medical Center; Estados UnidosFil: Ljubimova, Julia Y.. Cedars Sinai Medical Center; Estados UnidosFil: Helguera, Gustavo Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; ArgentinaFil: Penichet, Manuel L.. University of California at Los Angeles; Estados UnidosElsevier Science2012-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/14137Daniels, Tracy R.; Bernabeu, Ezequiel Adrian; Rodríguez, José A.; Patel, Shabnum; Kozman, Maggie; et al.; The transferrin receptor and the targeted delivery of therapeutic agents against cancer; Elsevier Science; Biochimica Et Biophysica Acta- General Subjects; 1820; 3; 3-2012; 291-3170304-4165enginfo:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S0304416511001826info:eu-repo/semantics/altIdentifier/doi/10.1016/j.bbagen.2011.07.016info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500658/info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T15:34:13Zoai:ri.conicet.gov.ar:11336/14137instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 15:34:13.505CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv The transferrin receptor and the targeted delivery of therapeutic agents against cancer
title The transferrin receptor and the targeted delivery of therapeutic agents against cancer
spellingShingle The transferrin receptor and the targeted delivery of therapeutic agents against cancer
Daniels, Tracy R.
Transferrin Receptor
Cancer
Nanoparticle
Immnunotoxin
Delivery
Conjugate
title_short The transferrin receptor and the targeted delivery of therapeutic agents against cancer
title_full The transferrin receptor and the targeted delivery of therapeutic agents against cancer
title_fullStr The transferrin receptor and the targeted delivery of therapeutic agents against cancer
title_full_unstemmed The transferrin receptor and the targeted delivery of therapeutic agents against cancer
title_sort The transferrin receptor and the targeted delivery of therapeutic agents against cancer
dc.creator.none.fl_str_mv Daniels, Tracy R.
Bernabeu, Ezequiel Adrian
Rodríguez, José A.
Patel, Shabnum
Kozman, Maggie
Chiappetta, Diego Andrés
Holler, Eggehard
Ljubimova, Julia Y.
Helguera, Gustavo Fernando
Penichet, Manuel L.
author Daniels, Tracy R.
author_facet Daniels, Tracy R.
Bernabeu, Ezequiel Adrian
Rodríguez, José A.
Patel, Shabnum
Kozman, Maggie
Chiappetta, Diego Andrés
Holler, Eggehard
Ljubimova, Julia Y.
Helguera, Gustavo Fernando
Penichet, Manuel L.
author_role author
author2 Bernabeu, Ezequiel Adrian
Rodríguez, José A.
Patel, Shabnum
Kozman, Maggie
Chiappetta, Diego Andrés
Holler, Eggehard
Ljubimova, Julia Y.
Helguera, Gustavo Fernando
Penichet, Manuel L.
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Transferrin Receptor
Cancer
Nanoparticle
Immnunotoxin
Delivery
Conjugate
topic Transferrin Receptor
Cancer
Nanoparticle
Immnunotoxin
Delivery
Conjugate
purl_subject.fl_str_mv https://purl.org/becyt/ford/2.10
https://purl.org/becyt/ford/2
dc.description.none.fl_txt_mv Background: Traditional cancer therapy can be successful in destroying tumors, but can also cause dangerous side effects. Therefore, many targeted therapies are in development. The transferrin receptor (TfR) functions in cellular iron uptake through its interaction with transferrin. This receptor is an attractive molecule for the targeted therapy of cancer since it is upregulated on the surface of many cancer types and is efficiently internalized. This receptor can be targeted in two ways: 1) for the delivery of therapeutic molecules into malignant cells or 2) to block the natural function of the receptor leading directly to cancer cell death. Scope of revie: In the present article we discuss the strategies used to target the TfR for the delivery of therapeutic agents into cancer cells. We provide a summary of the vast types of anti-cancer drugs that have been delivered into cancer cells employing a variety of receptor binding molecules including Tf, anti-TfR antibodies, or TfR-binding peptides alone or in combination with carrier molecules including nanoparticles and viruses. Major conclusions: Targeting the TfR has been shown to be effective in delivering many different therapeutic agents and causing cytotoxic effects in cancer cells in vitro and in vivo. General significance: The extensive use of TfR for targeted therapy attests to the versatility of targeting this receptor for therapeutic purposes against malignant cells. More advances in this area are expected to further improve the therapeutic potential of targeting the TfR for cancer therapy leading to an increase in the number of clinical trials of molecules targeting this receptor. This article is part of a Special Issue entitled Transferrins: molecular mechanisms of iron transport and disorders.
Fil: Daniels, Tracy R.. University of California at Los Angeles; Estados Unidos
Fil: Bernabeu, Ezequiel Adrian. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina
Fil: Rodríguez, José A.. University of California at Los Angeles; Estados Unidos
Fil: Patel, Shabnum. University of California at Los Angeles; Estados Unidos
Fil: Kozman, Maggie. University of California at Los Angeles; Estados Unidos
Fil: Chiappetta, Diego Andrés. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina
Fil: Holler, Eggehard. Cedars Sinai Medical Center; Estados Unidos
Fil: Ljubimova, Julia Y.. Cedars Sinai Medical Center; Estados Unidos
Fil: Helguera, Gustavo Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Tecnología Farmacéutica; Argentina
Fil: Penichet, Manuel L.. University of California at Los Angeles; Estados Unidos
description Background: Traditional cancer therapy can be successful in destroying tumors, but can also cause dangerous side effects. Therefore, many targeted therapies are in development. The transferrin receptor (TfR) functions in cellular iron uptake through its interaction with transferrin. This receptor is an attractive molecule for the targeted therapy of cancer since it is upregulated on the surface of many cancer types and is efficiently internalized. This receptor can be targeted in two ways: 1) for the delivery of therapeutic molecules into malignant cells or 2) to block the natural function of the receptor leading directly to cancer cell death. Scope of revie: In the present article we discuss the strategies used to target the TfR for the delivery of therapeutic agents into cancer cells. We provide a summary of the vast types of anti-cancer drugs that have been delivered into cancer cells employing a variety of receptor binding molecules including Tf, anti-TfR antibodies, or TfR-binding peptides alone or in combination with carrier molecules including nanoparticles and viruses. Major conclusions: Targeting the TfR has been shown to be effective in delivering many different therapeutic agents and causing cytotoxic effects in cancer cells in vitro and in vivo. General significance: The extensive use of TfR for targeted therapy attests to the versatility of targeting this receptor for therapeutic purposes against malignant cells. More advances in this area are expected to further improve the therapeutic potential of targeting the TfR for cancer therapy leading to an increase in the number of clinical trials of molecules targeting this receptor. This article is part of a Special Issue entitled Transferrins: molecular mechanisms of iron transport and disorders.
publishDate 2012
dc.date.none.fl_str_mv 2012-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/14137
Daniels, Tracy R.; Bernabeu, Ezequiel Adrian; Rodríguez, José A.; Patel, Shabnum; Kozman, Maggie; et al.; The transferrin receptor and the targeted delivery of therapeutic agents against cancer; Elsevier Science; Biochimica Et Biophysica Acta- General Subjects; 1820; 3; 3-2012; 291-317
0304-4165
url http://hdl.handle.net/11336/14137
identifier_str_mv Daniels, Tracy R.; Bernabeu, Ezequiel Adrian; Rodríguez, José A.; Patel, Shabnum; Kozman, Maggie; et al.; The transferrin receptor and the targeted delivery of therapeutic agents against cancer; Elsevier Science; Biochimica Et Biophysica Acta- General Subjects; 1820; 3; 3-2012; 291-317
0304-4165
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S0304416511001826
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.bbagen.2011.07.016
info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500658/
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier Science
publisher.none.fl_str_mv Elsevier Science
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846083471012790272
score 13.22299

Publicaciones similares